Business
Evolus to Report Third Quarter 2021 Results and Provide Business Update
NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on
About this update from Evolus, Inc. Common Stock
[{"type":"text","content":"NEWPORT BEACH, Calif., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets. Management will host a conference call and live webcast to discuss Evolus’ financial results at 9:00 a.m. ET that same day. A question-and-answer session will follow management’s remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of the Evolus website at www.evolus.com. Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international). An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com. About Evolus, Inc. Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com. Jeuveau® is a registered trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Evolus, Inc. Contacts: Investor/Media Contact:David K. Erickson, Evolus, Inc.Vice President, Investor RelationsTel: 949-966-1798Email: [email protected] \nSource: Evolus","length":3981,"tagName":"div"}]